4SC AG: 4SC announces Half-Year Report 2024 and provides update
Marketing Authorization Application (MAA) for resminostat (Kinselby) submitted to the European Medicines Agency (EMA…
Marketing Authorization Application (MAA) for resminostat (Kinselby) submitted to the European Medicines Agency (EMA…
Swissmedic has granted Orphan Drug Status for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODS benef…
4SC AG (4SC or "the Company") (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients sufferin…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 202…
Die 4SC AG (4SC, FWB Prime Standard: VSC) hat heute die Finanzergebnisse für das am 31. Dezember 2022 abgelaufene Geschä…
Die 4SC AG (4SC, FWB Prime Standard: VSC) hat heute die Finanzergebnisse für das am 31. Dezember 2021 abgelaufene Geschä…
Resminostat increases both cancer cell sensitivity towards natural killer (NK) cell-mediated killing and the direct kill…
RESMAIN - pivotal study to evaluate resminostat for maintenance treatment of patients with advanced-stage cutaneous T-ce…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC's collaboration partner Prof. Steven A. Johnsen and his t…